Core Laboratories reports mixed Q3 2026 results with a 2% year-over-year revenue decline and a 27% drop in adjusted EPS, despite sequential improvements in operating income.
Core Laboratories experienced a contraction in year-over-year performance, with revenue declining 2% and EPS falling 27% to $0.16 on an ex-items basis. Despite these annual declines, the company demonstrated sequential improvement, with revenue rising 6% and ex-items EPS increasing 46% compared to the previous quarter, suggesting a potential stabilization in operational efficiency.
The GAAP earnings per share was $0.12.
Ex-items operating income was $12.6 million, representing a 35% increase sequentially.
Core Laboratories reported Q3 2026 revenue of $132.1 million, marking a 2% decline compared to the previous year. While the company achieved a 35% sequential increase in adjusted operating income, earnings per share fell 27% year-over-year to $0.16 excluding items.
Core Laboratories saw a 2% decline in revenue and a 27% decrease in adjusted earnings per share compared to the same period last year.